Search

Displaying results 3651 - 3660 of 9715 in total
  1. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. [L4741] … A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities.

  2. Drug

    ADU-S100

    go.drugbank.com/drugs/DB14722
    Investigational

    ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune … ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system.

  3. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    Queuine is a derivative of [7-Deazaguanine]. Bacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals.

  4. Drug

    Cannabivarin

    go.drugbank.com/drugs/DB14736
    Experimental

    A natural product found in Cannabis sativa.

  5. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … Fundamentally, the N8-GP moiety is identical to [turoctocog alfa], a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the

  6. Drug

    PF-06459988

    go.drugbank.com/drugs/DB14768
    Investigational

    PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

  7. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  8. Drug

    Zatolmilast

    go.drugbank.com/drugs/DB14790
    Investigational

    BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).

  9. Drug

    RO-5045337

    go.drugbank.com/drugs/DB14793
    Investigational

    RO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).

  10. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).